ProfileGDS5678 / 1445198_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 66% 66% 65% 66% 67% 69% 71% 67% 65% 65% 67% 65% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6076659
GSM967853U87-EV human glioblastoma xenograft - Control 23.9831266
GSM967854U87-EV human glioblastoma xenograft - Control 33.9942566
GSM967855U87-EV human glioblastoma xenograft - Control 43.9360865
GSM967856U87-EV human glioblastoma xenograft - Control 53.9704366
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0844567
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.260969
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4861771
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.054767
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8718465
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8856765
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1087467
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9161265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9856166